Mylan Pharmaceuticals Inc. v. Novo Nordisk Inc. et al
| Mylan Pharmaceuticals Inc. |
| Novo Nordisk Inc. and Novo Nordisk A/S |
| 1:2026cv01192 |
| September 23, 2026 |
| U.S. District Court for the District of Delaware |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on September 24, 2026. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 5 Summons Issued as to Novo Nordisk Inc. on 9/24/2026. (aas) |
| Filing 4 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc., Other Affiliate Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (aas) |
| Filing 3 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 12,551,536 B2. (aas) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (aas) |
| Filing 1 COMPLAINT against Novo Nordisk A/S and Novo Nordisk Inc. (Filing fee $ 405, receipt number ADEDC-5072308.) - filed by Mylan Pharmaceuticals Inc.. (Attachments: #1 Exhibits A-F, #2 Civil Cover Sheet)(aas) |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
